DexCom
DXCM
905 hedge funds and large institutions have $42.9B invested in DexCom in 2023 Q1 according to their latest regulatory filings, with 92 funds opening new positions, 341 increasing their positions, 345 reducing their positions, and 91 closing their positions.
3% more capital invested
Capital invested by funds: $41.8B → $42.9B (+$1.14B)
1% more first-time investments, than exits
New positions opened: 92 | Existing positions closed: 91
0.02% more ownership
Funds ownership: 95.55% → 95.57% (+0.02%)
1% less repeat investments, than reductions
Existing positions increased: 341 | Existing positions reduced: 345
3% less call options, than puts
Call options by funds: $465M | Put options by funds: $478M
2% less funds holding
Funds holding: 919 → 905 (-14)
31% less funds holding in top 10
Funds holding in top 10: 26 → 18 (-8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$221M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$202M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$152M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$94.5M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$91.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$215M |
| 2 |
Janus Henderson Group
London,
|
-$212M |
| 3 |
Sands Capital Management
Arlington,
Virginia
|
-$199M |
| 4 |
Millennium Management
New York
|
-$136M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$93.6M |
DXCM Hedge Fund Activity: Q1 2023 in Review
905 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in DexCom (DXCM) for Q1 2023, worth a combined $42.9B — up 2.7% from $41.8B a quarter earlier.
Buyers outnumbered sellers: 92 funds opened new DXCM positions and 91 closed out — a net gain of 1 holder — while 341 added to existing stakes and 345 trimmed.
The largest buyer was Marshall Wace, adding an estimated $221M. The largest seller was Jennison Associates, cutting an estimated $215M.
- 905 institutional investors held DexCom (DXCM) as of Q1 2023, down from 919 in Q4 2022.
- Funds reported $42.9B of DexCom stock for Q1 2023, up 2.7% quarter-over-quarter.
- 92 funds opened new DexCom positions in Q1 2023 and 91 closed out, a net change of +1 holder.
- The largest DexCom buyer in Q1 2023 was Marshall Wace, an estimated $221M added.
- The largest DexCom seller in Q1 2023 was Jennison Associates, an estimated $215M sold.
Based on aggregated 13F filings for Q1 2023.